search
Back to results

A Trial of Intravascular Hypothermia Therapy in Acute Ischemic Stroke Patients

Primary Purpose

Hypothermia, Reperfusion Injury, Ischemic Stroke

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
ZOLL Intravascular Temperature Management system, Quattro catheter
Standard Treatment
Sponsored by
jiaoliqun
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypothermia

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age between 18 and 80 years old
  2. Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (internal carotid artery, middle cerebral artery M1 or M2 segment)
  3. ASPECTS score 0-10
  4. Arterial puncture could be performed within 24 hours from symptom onset or LKN
  5. Baseline NIHSS (NIHSS) score prior to randomization ≥ 10 and NIHSS 1a ≥ 1
  6. Candidate for endovascular thrombectomy therapy in accordance with best practices per AHA standard stroke guidelines meeting all labeling requirements for EVT in the trial
  7. Successful recanalization of occluded vessel (mTICI 2b-3) after EVT
  8. No intracranial hemorrhage postoperative CT examinations immediately after recanalization. If the subject' recanalization of vessel could not achieve mTICI 2b-3, the subject could not enter the per-protocol analysis and will separate another group
  9. Informed consent form signed by subjects or their legal guardian

Exclusion Criteria:

  1. Subject who suffer serious infection (e.g. sepsis) or multiple organ failure
  2. Known presence of an IVC filter
  3. End stage renal disease on hemodialysis
  4. Known hypersensitivity to antiplatelet agents, anticoagulation drugs, iodinated contrast and/or anesthetics
  5. Known hypersensitivity to the components of the medical device
  6. Any known history of the following conditions: bleeding diathesis, coagulopathy, cryoglobulinemia, sickle cell anemia, will refuse blood transfusions or contraindication to heparin; history of genetically confirmed hypercoagulable syndrome
  7. Use of warfarin with INR > 3
  8. Hemodynamically significant cardiac dysrhythmias (eg. QTc interval >450 msec, bradycardia (heart rate less than 50), Mobitz Type II second degree AV block (or higher AV block), and severe ventricular dysrhythmias (sustained VT or VF)) which cause significant hypotension (SBP ≤ 120 mmHg requiring more than two pressor medications)
  9. Platelet count<40×10^9/L
  10. Blood glucose concentration <2.7 or > 22.2 mmol/L
  11. Hypertension uncontrollable by drug treatment (systolic blood pressure≥185 mmHg or diastolic blood pressure≥110mmhg)
  12. Expected life expectancy<6 months
  13. Temperature < 35°C on admission to Emergency Department
  14. With a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness)
  15. Subject participating in a study involving an investigational drug or device that would impact the current study
  16. Baseline CT/MR evidence of multiple vascular territory acute stroke
  17. Baseline CT/MR showing evidence of arterial vasculitis or dissection
  18. Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy
  19. Evidence of intracranial hemorrhage or hemorrhagic transformation immediately after thrombectomy
  20. Presence of pulmonary embolism, ilio-femoral or deep vein thrombosis
  21. Brain vascular lesion (e.g. aneurysm or arteriovenous malformation)
  22. Brain tumor or CNS infection
  23. Concurrent participation in a study involving an investigational drug or device that would impact the current study
  24. Female patient of childbearing potential who is known to be pregnant or lactating
  25. For other reasons, the researchers believe that the patient is not suitable for continued treatment
  26. Patients without a legally authorized representative to sign the consent form will be excluded

Sites / Locations

  • Xuanwu HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Study group

Control group

Arm Description

Study Group: Intravascular hypothermia therapy group ZOLL Intravascular Temperature Management system, Quattro catheter will be used in study group

Control group: Without intravascular hypothermia therapy group ZOLL Intravascular Temperature Management system, Quattro catheter will not be used in control group

Outcomes

Primary Outcome Measures

Intracranial hemorrhage conversion rate
ICH

Secondary Outcome Measures

Modified Rankin scale (mRS)
The mRS is a 7-point scale ranging from 0 (no symptoms) to 6 (death)
The rate of functional independency (mRS 0-2)
The mRS is a 7-point scale ranging from 0 (no symptoms) to 6 (death)
The rate of mortality (mRS 6)
The mRS is a 7-point scale ranging from 0 (no symptoms) to 6 (death)
NIHSS
Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.
Rate of symptomatic intracranial hemorrhage (sICH)
The diagnosis of sICH was based on the association of ICH with any of the following. conditions: (1) Increase in NIHSS score > 4 points compared to the score before ICH; (2) Increase in NIHSS score by >2 points in one category; (3) deterioration leading to intubation, hemicraniectomy, external ventricular drain placement, or any other major interventions.
Rate of malignant cerebral edema
Development of signs of herniation (including decrease in consciousness and/or anisocoria), accompanied by midline shift >= 5 mm on follow-up imaging.
Infarct volume
measured on 5-7 days CT (or MRI if available)

Full Information

First Posted
January 1, 2021
Last Updated
June 1, 2022
Sponsor
jiaoliqun
search

1. Study Identification

Unique Protocol Identification Number
NCT04695236
Brief Title
A Trial of Intravascular Hypothermia Therapy in Acute Ischemic Stroke Patients
Official Title
A Prospective, Multicenter, Randomized Clinical Trial to Evaluate the Safety and Efficacy of Intravascular Hypothermia Therapy of Patients With Acute Ischemic Stroke
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 31, 2020 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
jiaoliqun

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Acute ischemic stroke (AIS) has been one of the major causes of global mortality and morbidity. The superiority of endovascular therapy (EVT) over standard medical therapy in treating AIS due to large vessel occlusion (LVO) in the anterior circulation has been widely accepted. However, a critical concern is that even with an extremely high rate of successful recanalization (the modified thrombolysis in cerebral infarction [mTICI] score 2b-3) around 90%, nearly half of the patients failed to benefit from EVT. So, adjunctive therapy of EVT for neuroprotection is required. From the previous domestic and foreign literatures, hypothermia can prevent and treat secondary injury caused by ischemia-reperfusion injury and cerebral edema of acute cerebral ischemia, so as to achieve the role of neuroprotection. In this study, intravascular cooling was performed as soon as possible with careful temperature control in patients receiving thrombectomy. The temperature was controlled at 33° C for 48-72 hours. This parallel controlled study is to systematically evaluate the feasibility and safety of adjunctive therapy using early intravascular hypothermia in AIS patients receiving mechanical thrombectomy. The results will clarify a potential modality for neuroprotection and hopefully provide new evidence in improving patient prognosis.
Detailed Description
In this study, the target subjects were AIS patients with successful recanalization (mTICI 2b-3). Early intravascular hypothermia neuroprotection therapy was given to patients after thrombectomy to evaluate its safety and effectiveness. The neuroprotection effect of endovascular hypothermia therapy is explored regarding several aspects, such as hemorrhagic conversion rate, cerebral edema, and neurological function recovery, with specific evaluation criteria described in detail in the following experimental design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypothermia, Reperfusion Injury, Ischemic Stroke, Thrombectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Assessment by independent investigators
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Study group
Arm Type
Experimental
Arm Description
Study Group: Intravascular hypothermia therapy group ZOLL Intravascular Temperature Management system, Quattro catheter will be used in study group
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Control group: Without intravascular hypothermia therapy group ZOLL Intravascular Temperature Management system, Quattro catheter will not be used in control group
Intervention Type
Device
Intervention Name(s)
ZOLL Intravascular Temperature Management system, Quattro catheter
Intervention Description
ZOLL Intravascular Temperature Management system, Quattro catheter
Intervention Type
Other
Intervention Name(s)
Standard Treatment
Intervention Description
Standard Treatment for Ischemic Strokre
Primary Outcome Measure Information:
Title
Intracranial hemorrhage conversion rate
Description
ICH
Time Frame
7 days after thrombectomy operation or discharge
Secondary Outcome Measure Information:
Title
Modified Rankin scale (mRS)
Description
The mRS is a 7-point scale ranging from 0 (no symptoms) to 6 (death)
Time Frame
90 days
Title
The rate of functional independency (mRS 0-2)
Description
The mRS is a 7-point scale ranging from 0 (no symptoms) to 6 (death)
Time Frame
90 days
Title
The rate of mortality (mRS 6)
Description
The mRS is a 7-point scale ranging from 0 (no symptoms) to 6 (death)
Time Frame
90 days
Title
NIHSS
Description
Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.
Time Frame
24 hours, 7 days or discharge
Title
Rate of symptomatic intracranial hemorrhage (sICH)
Description
The diagnosis of sICH was based on the association of ICH with any of the following. conditions: (1) Increase in NIHSS score > 4 points compared to the score before ICH; (2) Increase in NIHSS score by >2 points in one category; (3) deterioration leading to intubation, hemicraniectomy, external ventricular drain placement, or any other major interventions.
Time Frame
7 days after thrombectomy operation or discharge
Title
Rate of malignant cerebral edema
Description
Development of signs of herniation (including decrease in consciousness and/or anisocoria), accompanied by midline shift >= 5 mm on follow-up imaging.
Time Frame
7 days after thrombectomy operation or discharge
Title
Infarct volume
Description
measured on 5-7 days CT (or MRI if available)
Time Frame
5-7 days after thrombectomy operation or discharge
Other Pre-specified Outcome Measures:
Title
Rate of any major adverse events
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 18 and 80 years old Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (internal carotid artery, middle cerebral artery M1 or M2 segment) ASPECTS score 0-10 Arterial puncture could be performed within 24 hours from symptom onset or LKN Baseline NIHSS (NIHSS) score prior to randomization ≥ 10 and NIHSS 1a ≥ 1 Candidate for endovascular thrombectomy therapy in accordance with best practices per AHA standard stroke guidelines meeting all labeling requirements for EVT in the trial Successful recanalization of occluded vessel (mTICI 2b-3) after EVT No intracranial hemorrhage postoperative CT examinations immediately after recanalization. If the subject' recanalization of vessel could not achieve mTICI 2b-3, the subject could not enter the per-protocol analysis and will separate another group Informed consent form signed by subjects or their legal guardian Exclusion Criteria: Subject who suffer serious infection (e.g. sepsis) or multiple organ failure Known presence of an IVC filter End stage renal disease on hemodialysis Known hypersensitivity to antiplatelet agents, anticoagulation drugs, iodinated contrast and/or anesthetics Known hypersensitivity to the components of the medical device Any known history of the following conditions: bleeding diathesis, coagulopathy, cryoglobulinemia, sickle cell anemia, will refuse blood transfusions or contraindication to heparin; history of genetically confirmed hypercoagulable syndrome Use of warfarin with INR > 3 Hemodynamically significant cardiac dysrhythmias (eg. QTc interval >450 msec, bradycardia (heart rate less than 50), Mobitz Type II second degree AV block (or higher AV block), and severe ventricular dysrhythmias (sustained VT or VF)) which cause significant hypotension (SBP ≤ 120 mmHg requiring more than two pressor medications) Platelet count<40×10^9/L Blood glucose concentration <2.7 or > 22.2 mmol/L Hypertension uncontrollable by drug treatment (systolic blood pressure≥185 mmHg or diastolic blood pressure≥110mmhg) Expected life expectancy<6 months Temperature < 35°C on admission to Emergency Department With a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness) Subject participating in a study involving an investigational drug or device that would impact the current study Baseline CT/MR evidence of multiple vascular territory acute stroke Baseline CT/MR showing evidence of arterial vasculitis or dissection Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy Evidence of intracranial hemorrhage or hemorrhagic transformation immediately after thrombectomy Presence of pulmonary embolism, ilio-femoral or deep vein thrombosis Brain vascular lesion (e.g. aneurysm or arteriovenous malformation) Brain tumor or CNS infection Concurrent participation in a study involving an investigational drug or device that would impact the current study Female patient of childbearing potential who is known to be pregnant or lactating For other reasons, the researchers believe that the patient is not suitable for continued treatment Patients without a legally authorized representative to sign the consent form will be excluded
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Liqun Jiao,MD, PhD
Phone
13911224991
Email
liqunjiao@sina.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Xin Qu,MD
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Liqun Jiao,MD, PhD
Organizational Affiliation
Department of Neurosurgery & Interventional Neuroradiology Xuanwu Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xuanwu Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liqun Jiao,MD, Phd
Phone
86-10-83199060
Email
liqunjiao@sina.cn

12. IPD Sharing Statement

Learn more about this trial

A Trial of Intravascular Hypothermia Therapy in Acute Ischemic Stroke Patients

We'll reach out to this number within 24 hrs